Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 16/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20379338 | 0.80 | NAMPT (0.76) | NAMPTCYP2C9CYP2C19 | |
| SCHEMBL173773 | 0.79 | NAMPT (0.52) | NAMPTCYP2C9CYP2C19MAPTCYP3A4 | |
| SCHEMBL254831 | 0.79 | NAMPT (0.80) | NAMPTCYP2C9 | |
| Hydrochloric Acid SCHEMBL16107549 | 0.78 | NAMPT (0.51) | NAMPTCYP2C9CYP2C19MAPTCYP3A4 | |
| SCHEMBL30627386 | 0.78 | NAMPT (0.52) | NAMPTCYP2C9CYP2C19GAACYP3A4 | |
| SCHEMBL19754924 | 0.78 | NAMPT (0.73) | NAMPTCYP2C9CYP2C19 | |
| SCHEMBL15246421 | 0.77 | NAMPT (1.00) | NAMPTCYP2C9CYP2C19CYP3A4 | |
| SCHEMBL20388918 | 0.76 | NAMPT (0.77) | NAMPT | |
| SCHEMBL15690483 | 0.74 | CYP2C9 (0.50) | NAMPTCYP2C9CYP2C19CYP3A4 | |
| SCHEMBL20379512 | 0.71 | NAMPT (1.00) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210244717-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2021-08-12 | — | — | US | disclosed |
| US-20210244717-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2021-08-12 | — | — | US | disclosed |
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. | 2020-09-15 | — | — | US | disclosed |
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. | 2020-09-15 | — | — | US | disclosed |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-04-30 | — | — | US | disclosed |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-04-30 | — | — | US | disclosed |
| US-20190105307-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2019-04-11 | — | — | US | disclosed |
| US-20190105307-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2019-04-11 | — | — | US | disclosed |
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA TM, LLC (US) | 2017-12-28 | — | — | US | disclosed |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2014-10-02 | — | — | US | disclosed |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2014-10-02 | — | — | US | disclosed |
| EP-2611804-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Forma TM, LLC. (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012031197-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012031197-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190105307-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | NAMPT 1/4885CYP2C9 2180/4885CYP2C19 2860/4885 |
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NNT | NAMPT 1/4885CYP2C9 772/4885CYP2C19 1226/4885 |
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | NAMPT 1/4885CYP2C9 2180/4885CYP2C19 2860/4885 |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | NAMPT 1/4885CYP2C9 725/4885CYP2C19 1129/4885 |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | NAMPT 1/4885CYP2C9 2180/4885CYP2C19 2860/4885 |
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | NAMPT 1/4885CYP2C9 725/4885CYP2C19 1129/4885 |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | NAMPT 1/4885CYP2C9 725/4885CYP2C19 1129/4885 |
| US-20210244717-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | NAMPT 1/4885CYP2C9 2180/4885CYP2C19 2860/4885 |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | NAMPT 1/4885CYP2C9 2180/4885CYP2C19 2860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.